Biotech Analyst Cheng, along with Kenneth Kalunian, Professor of Medicine at UCSD, discuss Roivant (ROIV) Brepocitinib’s opportunity in SLE on an Analyst/Industry conference call to be held on November 1 at 1 pm. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ROIV:
- Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023
- Roivant Sciences participates in a conference call with JPMorgan
- Roivant (NASDAQ:ROIV) Gains after Roche’s $7.1 Billion Buy of Televant
- Roche to acquire Telavant from Roivant Sciences for $7.1B upfront
- Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant